Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Remdesivir · Veklury, GS-5734

Small molecule · Inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase · developed by Gilead Sciences

Approved FDA, Oct 2020

GILD Developer

1 Registered trials

What is Remdesivir?

Remdesivir is a nucleotide analog RNA polymerase inhibitor with activity against SARS-CoV-2. It is also studied in respiratory syncytial virus infection and other conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Veklury, GS-5734, RDV
Drug type: Small molecule
Targets: SARS-CoV-2 RNA-dependent RNA polymerase
Mechanism: Inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase
Pathways: viral RNA synthesis inhibition
Therapy area: Infectious disease
Developer: Gilead Sciences Inc (GILD)
FDA status: Approved as Veklury (October 22, 2020), NDA214787 · FDA label
UNII: 3QKI37EEHE

✅ FDA-approved uses

COVID-19 in hospitalized adults and pediatric patients
COVID-19 in non-hospitalized adults and pediatric patients with mild-to-moderate disease at high risk for progression

From the indications section of the FDA label (version of Jul 29, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06817889	Phase 2	Hematopoietic and Lymphatic System Neoplasm	Recruiting	GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autoimmune DiseaseHematopoietic and Lymphatic System NeoplasmRespiratory Syncytial Virus Infection

More from Gilead Sciences

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved Tenofovir Disoproxil FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Remdesivir

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z